60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Friday morning,Benzinga reports.

60 Degrees Pharmaceuticals Trading Down 3.7 %

Shares of SXTP stock opened at $1.05 on Friday. The stock has a market capitalization of $2.41 million, a price-to-earnings ratio of -0.10 and a beta of 4.40. 60 Degrees Pharmaceuticals has a 12-month low of $0.70 and a 12-month high of $13.20. The stock’s 50-day moving average price is $1.19 and its 200-day moving average price is $0.99.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow bought 35,823 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average price of $1.27 per share, with a total value of $45,495.21. Following the completion of the purchase, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This represents a 60.97 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 66,372 shares of company stock worth $82,410 over the last ninety days. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.